Tag Archives: IP

Does India's Glivec Decision Make April Fools of Us All?

By Helen Disney, Pugatch Consilium. On April 1, India’s Supreme Court denied an appeal challenging the rejection of a patent for Novartis’s cancer drug, Glivec. The drug is a life-saving medicine for certain forms of cancer, patented in nearly 40 other countries — including many which are not noted for the strength of their intellectual […]
Posted in Global, Guest Blog, IP, Legal, Op-Ed | Also tagged , , | 2 Comments

Global Patent Management Made Easy

Patent Management Made Easy Even with a successfully launched start-up or spin-out to your name, you may still be tempted to close your eyes to the complexities of IP. But it’s actually very simple, writes Jason Rutt. So, you have done it. You have left big business or forsaken the dusty halls of academia to […]
Posted in Europe, Global, Guest Blog, IP, Legal | Also tagged , , | 2 Comments

Fixing Innovation: Lilly's CEO Says Why, and How

Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, healthcare, IP, leadership, Legal, Market Access, Meetings, People, pricing, R&D, Regulatory, Safety, Strategy, Technology | Also tagged , , , , , , , , , , , , | 1 Comment

It's Industry's Problem: A Fresh Take on R&D Costs

High in-house failure rates are slowing progress on pricing affordability, says GSK CEO Andrew Witty. If there is one message that big pharma has applied consistently over the years, it is that drug development is very expensive. Big bucks and long-term investment in the institutional know-how and capacity built exclusively through private enterprise are what […]
Posted in Global, IP, leadership, R&D | Also tagged , , , | 2 Comments

Global Health Spotlight Turns to Chronic Disease

With donor fund levels sinking in the midst of a global fiscal crisis, multilateral institutions are finally having to face an issue they have avoided for years:  prioritizing time, people and resources to tackle a few health challenges rather than many. The UN Millennium Development Goals — now more than halfway toward a target completion […]
Posted in Global, healthcare, IP | Also tagged , , | 1 Comment
  • Categories

  • Meta